NASDAQ$NBIX

Neurocrine Biosciences Inc · Q4 2025 earnings

Q4 2025 earnings · · After market close · Investor relations

Briefing

Neurocrine Biosciences reported Q4 2025, net income of $45.0M, diluted EPS of $0.45.

For Q4 2025, Neurocrine Biosciences reported net income of $45.0M, diluted EPS was $0.45. Management discusses segment performance, liquidity, and outlook in the filing.

  • Net income $45.0M.
  • Diluted EPS $0.45.
  • Neurocrine Biosciences details capital allocation and 2026 priorities in the release.

Headline financials

Total Revenue

$806M

Previous: $628M+28.3%
EPS (adj)

$0.45

Previous: $1.69-73.4%
GAAP R&D Expense

$258M

Previous: $186M+39.1%
Non-GAAP R&D Expense

$234M

Previous: $164M+42.2%
GAAP SG&A Expense

$302M

Previous: $288M+4.9%
Non-GAAP SG&A Expense

$266M

Previous: $242M+9.9%
Acquired In-Process R&D

$17M

Previous: $3M+466.7%
Net Income

$45M

Previous: $103M-56.4%
Operating Income

$211M

Previous: $142M+48.5%

Revenue & EPS history

Neurocrine Biosciences · Revenue · Quarterly

$806M

Q4 2025+28.3%vs Q4 2024
Beat estimate in 11 of 15 quarters(73%)
ActualEstimate

Revenue by segment

Neurocrine Biosciences · $486M total across 1 segment · Q3 2023

  • INGREZZA Net Product Sales
    $486M+29.3%

Forward guidance

The filing discusses Neurocrine Biosciences's outlook, capital allocation, and key risks for upcoming periods beyond headline Q4 2025 results.

Tailwinds

  • Neurocrine Biosciences cites operational priorities supporting the forward outlook.
  • Balance sheet and liquidity support planned investments or returns.

Headwinds

  • Macro, input costs, or rates could pressure results versus plan.
  • Segment mix and one-time items may affect quarter-to-quarter comparability.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2025

Historical avgQ4 2025

-0.3%

Avg return

Earnings day

+1.1%

Avg return

5 days after

+1.6%

Avg return

30 days after

45%

29 / 65 earnings

Positive

+17.2%

Q3 2017

Best reaction

-18.5%

Q4 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.8%+11.5%+21.3%
Q4 2025-10.4%-7.0%-5.6%
Q3 2025-6.3%-3.7%+3.2%
Q1 2025+8.3%+5.4%+13.5%
Q4 2024-18.5%-22.1%-24.9%
Q3 2024+3.5%+3.7%+9.1%
Q2 2024+8.2%+2.9%-10.2%
Q1 2024+1.7%+3.0%-1.5%
Q4 2023-6.0%-8.8%-2.6%
Q3 2023+4.1%+5.0%+8.8%
Q2 2023+2.2%-0.3%+6.9%
Q1 2023-7.4%-5.4%-10.8%
Q4 2022-5.6%-6.2%-11.1%
Q3 2022+6.0%+5.8%+9.7%
Q2 2022+10.6%+14.5%+9.5%
Q1 2022-3.9%-14.6%+7.7%
Q4 2021+8.7%+7.9%+12.2%
Q3 2021-9.3%-11.6%-23.4%
Q2 2021-2.8%-6.6%+0.4%
Q1 2021-2.3%-0.3%+3.2%
Q4 2020+3.1%+2.6%-17.3%
Q3 2020-9.1%-4.5%-4.5%
Q2 2020-0.2%-4.4%-3.7%
Q1 2020+7.0%+11.6%+13.8%
Q4 2019+2.0%+3.5%-5.4%
Q3 2019-1.2%+6.9%+14.4%
Q2 2019+9.7%+7.5%+11.3%
Q1 2019-6.7%+2.0%+1.4%
Q4 2018-4.6%-4.6%-12.9%
Q3 2018-8.0%-9.0%-25.5%
Q2 2018+14.7%+17.2%+23.3%
Q1 2018+3.3%+1.5%+17.1%
Q4 2017+3.9%+3.7%+11.6%
Q3 2017+17.2%+20.0%+18.5%
Q2 2017+10.2%+10.5%+17.4%
Q1 2017+3.4%+3.8%-15.3%
Q4 2016+0.7%+4.5%+7.2%
Q3 2016-10.0%-1.1%-3.1%
Q2 2016-0.7%-3.6%-2.0%
Q1 2016-0.1%
Q4 2015+6.9%
Q3 2015-4.5%
Q2 2015-3.7%
Q1 2015-4.4%
Q4 2014+5.7%
Q3 2014-4.9%
Q2 2014-2.3%
Q1 2014-3.5%
Q4 2013+1.3%
Q3 2013-6.3%
Q2 2013+0.5%
Q1 2013+2.3%
Q4 2012+6.5%
Q3 2012-1.7%
Q2 2012-9.6%
Q1 2011-3.2%
Q1 2012-3.2%
Q4 2011-8.0%
Q4 2009-8.0%
Q3 2010+13.7%
Q3 2011+13.7%
Q4 2010-6.5%
Q2 2010-6.5%
Q2 2011-6.5%
Q1 2010-1.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro